Acute myeloid leukaemia (AML) is mainly characterized by an increase in the number of myeloid cells in the bone marrow and a decrease in mature cells, accounting for 28% of leukaemia cases, with a ...

Acute myeloid leukemia (AML) has particularly poor outcomes ... Patients received induction chemotherapy with oblimersen, cytarabine and daunorubicin. Further doses of oblimersen and high-dose ...

The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated ...

and engaged leading contract research organization (CRO); On track to begin dosing of Annamycin in combination with cytarabine for the treatment of R/R AML in Q1 2025 – Expected timelines for ...

Arms A and B will compare the therapy and a placebo, both in conjunction with cytarabine and anthracycline ... in this broader population of patients with AML, who are in need of new treatment ...

Received US Institutional Review Board (IRB) approval for pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) and engaged leadingcontract research organization (CRO); On track to begin ...

The FDA’s approval covers use of Venclexta (venetoclax) in combination with azacytidine, or decitabine, or low-dose cytarabine (LDAC) for newly diagnosed AML in adults 75 years or older ...

This trial is comparing venetoclax and azacitidine with azacitidine for acute myeloid leukaemia (AML). Read more about A trial of venetoclax and azacitidine for acute myeloid leukaemia (VIALE M) A ...

FLT3 is a receptor tyrosine kinase protein that plays an important role in blood cell development but, when constitutively activated, FLT3 can contribute to AML development and growth. Vanflyta is an ...